 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
Background: Although insulin secretion is severely decreased in most patients with type 1 diabetes, levels of residual insulin secretion often vary early in the disease. The significance of residual insulin secretion with regard to metabolic control and to long-term complications and ways to preserve such secretion are not well understood.
Objective: To compare the effects of intensive and conventional therapy on residual insulin secretion in Diabetes Control and Complications Trial (DCCT) participants.
Design: Multicenter, randomized, controlled clinical trial.
Setting: 29 DCCT clinical centers.
Patients: 855 of the 1441 DCCT participants had had type 1 diabetes for 1 to 5 years at baseline. Of these 855 patients, 303 were C-peptide responders (C-peptide level, 0.20 to 0.50 pmol/mL after ingestion of a standardized, mixed meal); 138 of these patients were randomly assigned to intensive therapy, and 165 were assigned to conventional therapy. Five hundred fifty-two patients were nonresponders (stimulated C-peptide level < 0.2 pmol/mL); 274 of these patients were assigned to intensive therapy, and 278 were assigned to conventional therapy.
Interventions: 1] Intensive therapy with 3 or more insulin injections daily or continuous subcutaneous infusion of insulin, guided by 4 or more glucose tests per day or 2) conventional therapy with 1 or 2 insulin injections daily.
Measurements: Stimulated C-peptide level was measured annually in responders. Development of retinopathy and microalbuminuria was assessed annually, hemoglobin A1c levels were measured quarterly, and episodes of hypoglycemia were ascertained quarterly.
Results: Responders receiving intensive therapy maintained a higher stimulated C-peptide level and a lower likelihood of becoming nonresponders than did responders receiving conventional therapy (risk reduction, 57% [95% CI, 39% to 71%]; P < 0.001). As in the entire DCCT cohort, intensively treated responders had a reduced risk for retinopathy progression and development of microalbuminuria and a higher risk for severe hypoglycemia compared with conventionally treated responders. Among intensively treated patients, responders had a lower hemoglobin A1c value (P < 0.01), a 50% (95% CI, 12% to 72%) reduced risk for retinopathy progression, and a lower risk for severe hypoglycemia (risk reduction, 65% [CI, 53% to 74%]; P < 0.001) compared with nonresponders.
Conclusions: Intensive therapy for type 1 diabetes helps sustain endogenous insulin secretion, which, in turn, is associated with better metabolic control and lower risk for hypoglycemia and chronic complications. These observations underscore the importance of initiating intensive diabetic management as early as safely possible after type 1 diabetes is diagnosed.
Author and Article Information
The Diabetes Control and Complications Trial Research Group.
ARTICLE
Effect of Intensive Therapy on Residual ß-Cell Function in Patients with Type 1 Diabetes in the Diabetes Control and Complications Trial
A Randomized, Controlled Trial
1 April 1998 | Volume 128 Issue 7 | Pages 517-523
This article has been cited by other articles:
|
|
 |
|
  A. Rewers, G. Klingensmith, C. Davis, D. B. Petitti, C. Pihoker, B. Rodriguez, I. D. Schwartz, G. Imperatore, D. Williams, L. M. Dolan, et al. Presence of Diabetic Ketoacidosis at Diagnosis of Diabetes Mellitus in Youth: The Search for Diabetes in Youth Study Pediatrics, May 1, 2008; 121(5): e1258 - e1266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. T. Bloomgarden Type 1 Diabetes and Glucose Monitoring Diabetes Care, November 1, 2007; 30(11): 2965 - 2971. [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Voltarelli, C. E. B. Couri, A. B. P. L. Stracieri, M. C. Oliveira, D. A. Moraes, F. Pieroni, M. Coutinho, K. C. R. Malmegrim, M. C. Foss-Freitas, B. P. Simoes, et al. Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus JAMA, April 11, 2007; 297(14): 1568 - 1576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. ABLAMUNITS, N. A. SHERRY, J. A. KUSHNER, and K. C. HEROLD Autoimmunity and beta Cell Regeneration in Mouse and Human Type 1 Diabetes: The Peace Is Not Enough Ann. N.Y. Acad. Sci., April 1, 2007; 1103(1): 19 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Sosenko, J. P. Palmer, C. J. Greenbaum, J. Mahon, C. Cowie, J. P. Krischer, H. P. Chase, N. H. White, B. Buckingham, K. C. Herold, et al. Increasing the Accuracy of Oral Glucose Tolerance Testing and Extending Its Application to Individuals With Normal Glucose Tolerance for the Prediction of Type 1 Diabetes: The Diabetes Prevention Trial-Type 1 Diabetes Care, January 1, 2007; 30(1): 38 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Sosenko, J. P. Palmer, C. J. Greenbaum, J. Mahon, C. Cowie, J. P. Krischer, H. P. Chase, N. H. White, B. Buckingham, K. C. Herold, et al. Patterns of metabolic progression to type 1 diabetes in the diabetes prevention trial-type 1. Diabetes Care, March 1, 2006; 29(3): 643 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Wittlin Treating the Spectrum of Type 2 Diabetes: Emphasis on Insulin Pump Therapy The Diabetes Educator, January 1, 2006; 32(1): 39S - 46S. [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Sherry, E. B. Tsai, and K. C. Herold Natural History of {beta}-Cell Function in Type 1 Diabetes Diabetes, December 1, 2005; 54(suppl_2): S32 - S39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Narendran, E. Estella, and S. Fourlanos Immunology of type 1 diabetes QJM, August 1, 2005; 98(8): 547 - 556. [Full Text] [PDF]
|
|
|
|
 |
|
 E. D'Amico, H. Hui, N. Khoury, U. Di Mario, and R. Perfetti Pancreatic {beta}-cells expressing GLP-1 are resistant to the toxic effects of immunosuppressive drugs J. Mol. Endocrinol., April 1, 2005; 34(2): 377 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Stoneking Initiating basal insulin therapy in patients with type 2 diabetes mellitus Am. J. Health Syst. Pharm., March 1, 2005; 62(5): 510 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Ryan, B. W. Paty, P. A. Senior, J. R.T. Lakey, D. Bigam, and A.M. J. Shapiro {beta}-Score: An assessment of {beta}-cell function after islet transplantation Diabetes Care, February 1, 2005; 28(2): 343 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. ERGUN-LONGMIRE, J. MARKER, A. ZEIDLER, R. RAPAPORT, P. RASKIN, B. BODE, D. SCHATZ, A. VARGAS, D. ROGERS, S. SCHWARTZ, et al. Oral Insulin Therapy to Prevent Progression of Immune-Mediated (Type 1) Diabetes Ann. N.Y. Acad. Sci., December 1, 2004; 1029(1): 260 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ortqvist, E. Bjork, M. Wallensteen, J. Ludvigsson, J. Aman, C. Johansson, G. Forsander, F. Lindgren, L. Berglund, M. Bengtsson, et al. Temporary Preservation of {beta}-Cell Function by Diazoxide Treatment in Childhood Type 1 Diabetes Diabetes Care, September 1, 2004; 27(9): 2191 - 2197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chen, S. S. Yan, J. Colgan, H.-P. Zhang, J. Luban, A. M. Schmidt, D. Stern, and K. C. Herold Blockade of Late Stages of Autoimmune Diabetes by Inhibition of the Receptor for Advanced Glycation End Products J. Immunol., July 15, 2004; 173(2): 1399 - 1405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Steele, W. A. Hagopian, S. Gitelman, U. Masharani, M. Cavaghan, K. I. Rother, D. Donaldson, D. M. Harlan, J. Bluestone, and K. C. Herold Insulin Secretion in Type 1 Diabetes Diabetes, February 1, 2004; 53(2): 426 - 433. [Abstract] [Full Text]
|
|
|
|
|
|
J. P. Palmer, G. A. Fleming, C. J. Greenbaum, K. C. Herold, L. D. Jansa, H. Kolb, J. M. Lachin, K. S. Polonsky, P. Pozzilli, J. S. Skyler, et al. C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve {beta}-Cell Function: Report of an ADA Workshop, 21-22 October 2001 Diabetes, January 1, 2004; 53(1): 250 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Hirshberg, K. I. Rother, B. J. Digon III, J. Lee, J. L. Gaglia, K. Hines, E. J. Read, R. Chang, B. J. Wood, and D. M. Harlan Benefits and Risks of Solitary Islet Transplantation for Type 1 Diabetes Using Steroid-Sparing Immunosuppression: The National Institutes of Health experience Diabetes Care, December 1, 2003; 26(12): 3288 - 3295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. DeWitt and I. B. Hirsch Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: Scientific Review JAMA, May 7, 2003; 289(17): 2254 - 2264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Greenbaum and L. C. Harrison Guidelines for Intervention Trials in Subjects With Newly Diagnosed Type 1 Diabetes Diabetes, May 1, 2003; 52(5): 1059 - 1065. [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Hoeldtke, K. D. Bryner, D. R. McNeill, S. S. Warehime, K. Van Dyke, and G. Hobbs Oxidative Stress and Insulin Requirements in Patients with Recent-Onset Type 1 Diabetes J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1624 - 1628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Steffes, S. Sibley, M. Jackson, and W. Thomas {beta}-Cell Function and the Development of Diabetes-Related Complications in the Diabetes Control and Complications Trial Diabetes Care, March 1, 2003; 26(3): 832 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Palmer and I. B. Hirsch What's in a Name: Latent autoimmune diabetes of adults, type 1.5, adult-onset, and type 1 diabetes Diabetes Care, February 1, 2003; 26(2): 536 - 538. [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Herold, W. Hagopian, J. A. Auger, E. Poumian-Ruiz, L. Taylor, D. Donaldson, S. E. Gitelman, D. M. Harlan, D. Xu, R. A. Zivin, et al. Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus N. Engl. J. Med., May 30, 2002; 346(22): 1692 - 1698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A.M. Gale Can We Change the Course of Beta-Cell Destruction in Type 1 Diabetes? N. Engl. J. Med., May 30, 2002; 346(22): 1740 - 1742. [Full Text] [PDF]
|
|
|
|
|
|
The Writing Team for the Diabetes Control and Comp Effect of Intensive Therapy on the Microvascular Complications of Type 1 Diabetes Mellitus JAMA, May 15, 2002; 287(19): 2563 - 2569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Nathan The Impact of Clinical Trials on the Treatment of Diabetes Mellitus J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 1929 - 1937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Krishnamurti and M. W. Steffes Glycohemoglobin: A Primary Predictor of the Development or Reversal of Complications of Diabetes Mellitus Clin. Chem., July 1, 2001; 47(7): 1157 - 1165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Klingensmith, R. Temple-Trujillo, and D. Johnson Pump Therapy for Children: Weighing the Risks and Benefits: View 1: The Cons of Insulin Pump Therapy in the Young Child Diabetes Spectr, April 1, 2001; 14(2): 81 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Maniatis, G. J. Klingensmith, R. H. Slover, C. J. Mowry, and H. P. Chase Continuous Subcutaneous Insulin Infusion Therapy for Children and Adolescents: An Option for Routine Diabetes Care Pediatrics, February 1, 2001; 107(2): 351 - 356. [Abstract] [Full Text]
|
|
|
|
|
|
W. V. Tamborlane and M. Grey Is Strict Glycemic Control of Diabetes Necessary and Feasible in Most Children and Adolescents? J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 515 - 518. [Full Text]
|
|
|
|
 |
|
 J. Dalewitz, N. Khan, and C. O. Hershey Barriers to Control of Blood Glucose in Diabetes Mellitus American Journal of Medical Quality, January 1, 2000; 15(1): 16 - 25. [Abstract] [PDF]
|
|
|
|
 |
|
 B J. Muhammad, P. G F Swift, N. T Raymond, and J. L Botha Partial remission phase of diabetes in children younger than age 10 years Arch. Dis. Child., April 1, 1999; 80(4): 367 - 369. [Abstract] [Full Text]
|
|
Article
